Bernadette Connaughton
Direktor/Vorstandsmitglied bei HALOZYME THERAPEUTICS, INC.
Vermögen: 3 Mio $ am 30.04.2024
Aktive Positionen von Bernadette Connaughton
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
HALOZYME THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 10.09.2018 | - |
Independent Dir/Board Member | 10.09.2018 | - | |
ZEALAND PHARMA A/S | Direktor/Vorstandsmitglied | 04.04.2019 | - |
Independent Dir/Board Member | 04.04.2019 | - | |
EDITAS MEDICINE, INC. | Direktor/Vorstandsmitglied | 26.10.2021 | - |
Independent Dir/Board Member | 26.10.2021 | - | |
Boys & Girls Clubs of New Jersey | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Bernadette Connaughton
Ehemalige bekannte Positionen von Bernadette Connaughton
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SYNEOS HEALTH, INC. | Direktor/Vorstandsmitglied | 12.11.2019 | 28.09.2023 |
Independent Dir/Board Member | 12.11.2019 | 28.09.2023 | |
VISTERRA INC | Direktor/Vorstandsmitglied | 01.12.2015 | 01.08.2018 |
Bristol-Myers Squibb Pharma Co. | Corporate Officer/Principal | 01.01.2004 | 01.10.2017 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2004 | 01.01.2017 |
Ausbildung von Bernadette Connaughton
The Johns Hopkins University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 10 |
Dänemark | 2 |
Operativ
Director/Board Member | 6 |
Independent Dir/Board Member | 4 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 7 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
HALOZYME THERAPEUTICS, INC. | Health Technology |
ZEALAND PHARMA A/S | Health Technology |
EDITAS MEDICINE, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Visterra, Inc.
Visterra, Inc. Pharmaceuticals: MajorHealth Technology Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA. | Health Technology |
Bristol-Myers Squibb Pharma Co. | |
Boys & Girls Clubs of New Jersey | |
Syneos Health, Inc.
Syneos Health, Inc. BiotechnologyHealth Technology Syneos Health, Inc. engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. It also offers individual services including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, and consultancy services. The company was founded in 1998 and is headquartered in Morrisville, NC. | Health Technology |
- Börse
- Insiders
- Bernadette Connaughton
- Erfahrung